![](./P020230913592750978326_r65.jpg)
Feng Wang, Ph.D, Prof.
-
Principal Investigator
Laboratory of Protein and Peptide Drugs, IBP
Research Interests: (1) Protein engineering and Biomolecular drug development; (2) Anti-tuberculosis drug discovery and development; (3) Chenical biology / Synthetic biology
Email: wangfeng@ibp.ac.cn
Tel: 010-64881052
Address: 15 Datun Road, Chaoyang District, Beijing, 100101, China
Chinese personal homepage
- Biography
1993 - 1998 B.S. , University of Science and Technology of China
1998 - 2000 M.S., Northwestern University
2003 - 2007 Ph.D., Texas A&M University
2007 - 2012 Postdoctoral Fellow, The Scripps Research Institute
2012 - 2017 Principal Investigator, California Institute for Biomedical Research
2017 - Professor, Institute of Biophysics, Chinese Academy of Sciences
- Awards
- Membership in Academies & Societies
- Research Interests
· Infectious and Tropical Disease
· Oncology
· Metabolic and Cardiovascular Disease
· Autoimmune and Inflammatory Disease
· Tissue-specific Therapeutic Strategies
· Enhancing the Pharmacology of Therapeutic Proteins and Peptides
· Bispecific Antibodies and Engineered T cells
- Grants
- Selected Publications
1. Longxin Chen, Chaoyang Zhu, Hui Guo, Runting Li, Limeng Zhang, Zhenzhen Xing, Yue Song, Zihan Zhang, Fuping Wang, Xiaofeng Liu, Yuhan Zhang, Runlin Z. Ma, Feng Wang. , Sci. Adv. 2020; 6:aaz7825.
2. Yuhan Zhang, Changming Fang, Rongsheng E. Wang, Ying Wang, Hui Guo, Chao Guo, Lijun Zhao, Shuhong Li, Xia Li, Peter G. Schultz, Yu J. Cao, and Feng Wang*, A tumor-targeted immune checkpoint blocker. Proc. Natl. Acad. Sci. U S A., 2019 116 (32) 15889-15894.
3. Harbut MB, Yang BY, Liu RH, Yano T, VilchHze C, Cheng B, Lockner J, Guo H, Yu CG, Franzblau SG, Petrassi M, Jacobs WRJ, Rubin H, Chatterjee AK, and Feng Wang*, Small Molecules Targeting Mycobacterium tuberculosis Type II NADH Dehydrogenase Exhibit Antimycobacterial Activity. Angew Chem. Int. Ed. Engl. 2018, 57, 3478 –3482.
4. Na Chen, Siqi Xu, Yuhan Zhang, Feng Wang*, Animal protein toxins: origins and therapeutic applications. Biophys Rep 2018, 4(5):233–242.
5. Du JJ, Cao Y, Liu Y, Wang Y, Zhang Y, Fu GS, Zhang YH, Lu L, Luo XZ, Kim CH, Schultz PG, Feng Wang*, Engineering bifunctional antibodies with constant region fusion architectures. J. Am. Chem. Soc., 2017,139, 18607-18615.
6. Renhe Liu, Xiaoxuan Lyu, Sarah M Batt, Mei-Hui Hsu, Michael B Harbut, Catherine Vilchèze, Bo Cheng, Kehinde Ajayi, Baiyuan Yang, Yun Yang, Hui Guo, Changyou Lin, Fei Gan, Chen Wang, Scott G. Franzblau, William R. Jacobs Jr., Gurdyal S. Besra, Eric F. Johnson, Mike Petrassi, Arnab K. Chatterjee, Klaus Fütterer, Feng Wang*, Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes, Angew Chem. Int. Ed. Engl., 2017, 56,13011-13015
7. Xiaozhou Luo, Guangsen Fu, Rongsheng E. Wang, Xueyong Zhu, Claudio Zambaldo, Renhe Liu, Tao Liu, Xiaoxuan Lyu, Jintang Du, Weimin Xuan, Anzhi Yao, Sean A. Reed, Mingchao Kang, Yuhan Zhang, Hui Guo, Chunhui Huang, Peng-Yu Yang, Ian A. Wilson, Peter G. Schultz, and Feng Wang*, Genetically encoding phosphotyrosine and its nonhydrolyzable analog in bacteria, Nat. Chem. Biol.,2017, 13,845-849
8. Ying Wang, Jintang Du, Huafei Zou, Yan Liu, Yuhan Zhang, Jose Gonzalez, Elizabeth Chao, Lucy Lu, Holly Parker, Van Nguyen-Tran, Weijun Shen, Danling Wang, Peter G. Schultz, and Feng Wang*, Multi-functional Antibody Agonists Targeting Glucagon-like Peptide-1, Glucagon, and Glucose-dependent Insulinotropic Polypeptide Receptors, Angew Chem. Int. Ed. Engl., 2016, 55, 12475–12478
9. Yan Liu, Ying Wang, Yong Zhang, Tao Liu, Haiqun Jia, Huafei Zou, Qiangwei Fu, Yuhan Zhang, Lucy Lu, Elizabeth Chao, Holly Parker, Van Nguyen-Tran, Weijun Shen, Danling Wang, Peter G. Schultz*, and Feng Wang*, Rational Design of Dual Agonist-Antibody Fusions as Long-acting Therapeutic Hormones, ACS Chem. Biol., 2016, 11, 2991-2995
10. Rongsheng E. Wang, Ying Wang, Yuhan Zhang, Chase Gabrelow, Yong Zhang, Victor Chi, Qiangwei Fu, Xiaozhou Luo, Danling Wang, Sean Joseph, Kristen Johnson, Arnab Chatterjee, Timothy M. Wright, Van Nguyen-Tran, John Tejaro, Argyrios N. Theofilopoulos, Peter G. Schultz, Feng Wang*, Rational Design of a Kv1.3 Channel Blocking Antibody as a Selective Immunosuppressant, Proc. Natl. Acad. Sci. U S A., 2016, 113, 11501–11506
11. Xiaozhou Luo, Tao Liu, Ying Wang, Haiqun Jia, Yuhan Zhang, Dawna Caballero, Juanjuan Du, Rongsheng E. Wang, Danling Wang, Peter G. Schultz and Feng Wang*, An Epitope-Specific Respiratory Syncytial Virus Vaccine based on an Antibody Scaffold, Angew Chem. Int. Ed. Engl., 2015, 54, 14531-14534
12. Tao Liu, Juanjuan Du, Xiaozhou Luo, Peter G Schultz, Feng Wang*, Homogeneously modified immunoglobulin domains for therapeutic application, Curr Opin Chem Biol., 2015, 28, 66-74
13. Michael B. Harbut, Catherine Vilchèze, Xiaozhou Luo, Mary E. Hensler, Hui Guo, Baiyuan Yang, Arnab K. Chatterjee, Victor Nizet, William R. Jacobs Jr., Peter G. Schultz, and Feng Wang*, Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis, Proc. Natl. Acad. Sci. U S A., 2015, 112, 4453-4458
14. Tao Liu, Guangsen Fu, Xiaozhou Luo, Yan Liu, Ying Wang, Rongsheng Wang, Peter G. Schultz, and Feng Wang*, Rational design of antibody protease inhibitors, J. Am. Chem. Soc., 2015, 137, 4042-4045
15. Rongsheng Wang, Tao Liu, Ying Wang, Yu Cao, Jintang Du, Xiaozhou Luo, Vishal Deshmukh, Chan Hyuk Kim, Brian R. Lawson, Matthew S. Tremblay, Travis S. Young, Stephanie A. Kanzane, Feng Wang*, and Peter G. Schultz*, An immunosuppressive antibody-drug conjugate, J. Am. Chem. Soc., 2015, 137, 3229-3232
16. Tao Liu, Yong Zhang, Yan Liu, Ying Wang, Haiqun Jia, Mingchao Kang, Xiaozhou Luo, Dawna Caballero, Jose Gonzalez, Danling Wang, Ashley Woods, Peter G. Schultz and Feng Wang*, Functional Human Antibody CDR Fusions as Long-Acting Therapeutic Endocrine Agonists, Proc. Natl. Acad. Sci. U S A., 2015, 112, 1356-1361
17. Yong Zhang, Huafei Zou, Ying Wang, Dawna Caballero, Jose Gonzalez, Elizabeth Chao, Gus Welzel, Weijun Shen, Danling Wang, Peter G. Schultz and Feng Wang*, Rational Design of a Humanized Glucagon-Like Peptide-1 Receptor Agonist Antibody, Angew Chem. Int. Ed. Engl., 2015, 54, 2126-2130
18. Yong Zhang, Yan Liu, Ying Wang, Peter G. Schultz and Feng Wang*, Rational Design of Humanized Dual-Agonist Antibodies, J. Am. Chem. Soc., 2015, 137, 38-41
19. Tao Liu, Yan Liu, Ying Wang, Mitchell Hull, Peter G. Schultz, and Feng Wang*, Rational design of CXCR4 specific antibodies with elongated CDRs, J. Am. Chem. Soc., 2014, 136, 10557-60
20. Yong Zhang, Devrishi Goswami, Danling Wang, Tsung-Shing Andrew Wang, Shiladitya Sen, Thomas J. Magliery, Patrick R. Griffin, Feng Wang*, and Peter G. Schultz, An Antibody with a Variable Region Coiled-Coil “Knob” Domain, Angew Chem. Int. Ed. Engl., 2014, 5, 132-135
21. Yong Zhang, Danling Wang, Gus Welzel, Ying Wang, Peter G. Schultz, and Feng Wang*, An Antibody CDR3-Erythropoietin Fusion Protein, ACS Chem. Biol., 2013, 8, 2117-2121
22. Yong Zhang, Danling Wang, Lorenzo de Lichtervelde, Sophie B. Sun, Vaughn V. Smider, Peter G. Schultz, Feng Wang*, Functional Antibody CDR3 Fusion Proteins with Enhanced Pharmacological Properties, Angew Chem. Int. Ed. Engl., 2013, 52, 8295-8298
23. Feng Wang, Dhinakaran Sambandan, Rajkumar Halder, Jianing Wang, Sarah M. Batt, Brian Weinrick, Insha Ahmad, Pengyu Yang, Yong Zhang, John Kim, Morad Hassani, Stanislav Huszar, Claudia Trefzer, Zhenkun Ma, Takushi Kaneko, Khisi E. Mdluli, Scott Franzblau, Arnab K. Chatterjee, Kai Johnson, Katarina Mikusova, Gurdyal S. Besra, Klaus Fütterer, William R. Jacobs, Jr., and Peter G. Schultz, Identification of a small molecule with activity against drug-resistant and persistent tuberculosis, Proc. Natl. Acad. Sci. U S A., 2013, 110, E2510-E2517
24. Feng Wang, Damian C. Ekiert, Insha Ahmad, Wenli Yu, Yong Zhang, Omar Bazirgan, Ali Torkamani, Terje Raudsepp, Waithaka Mwangi, Michael F. Criscitiello, Ian A. Wilson, Peter G. Schultz, Vaughn V. Smider, Reshaping antibody diversity, Cell, 2013, 153, 1379-1393
(From Feng Wang, November 13, 2020)